Xencor Remediates Material Weaknesses, Reports Strong Partnered Pipeline Progress & Reduced Net Loss
Summary
Xencor announced the full remediation of material weaknesses in internal controls, reported significant progress for partnered clinical programs including a Phase 3 success and planned BLA submission, and a reduced net loss for 2025, while continuing to navigate patent litigation.
Key Events
-
Material Weaknesses Remediation
Xencor announced the full remediation of previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2025, enhancing financial reporting reliability.
-
Partnered Pipeline Advancement
Partner Zenas BioPharma reported positive Phase 3 results for obexelimab in IgG4-RD, with a Biologics License Application (BLA) submission anticipated in Q2 2026. Additionally, Amgen initiated a Phase 3 study for xaluritamig in metastatic castration-resistant prostate cancer.
-
Reduced Net Loss
The company reported a net loss of $91.9 million for 2025, a significant improvement from the $232.6 million net loss in 2024, partly driven by $101.5 million in gains on marketable equity securities.
-
Ongoing Patent Litigation
Xencor is actively defending against a patent infringement lawsuit filed by Merus N.V., with a hearing on a motion to dismiss an amended complaint held in February 2026 and *inter partes* review granted for certain patents.
Analysis
This 10-K filing highlights significant positive developments for Xencor. The full remediation of previously disclosed material weaknesses in internal control over financial reporting is a crucial step in strengthening corporate governance and investor confidence. Furthermore, the advancement of partnered assets, particularly Zenas BioPharma's obexelimab with positive Phase 3 results and a planned BLA submission, and Amgen's initiation of a Phase 3 study for xaluritamig, validates Xencor's technology platform and signals potential future royalty streams. While the ongoing patent litigation with Merus N.V. presents a material risk, the company is actively defending its position. The substantial reduction in net loss and a cash runway through 2028 provide a more stable financial outlook for the clinical-stage biopharmaceutical company.
At the time of this filing, XNCR was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $855.5M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.